Most Popular Stories
Poll
Featured Jobs
-
New Jersey PA or NP
StaffPointe, LLC - northeast, NJ -
Florida Cardiologist
StaffPointe, LLC - near Tampa, FL -
Tennessee Occupational Medicine
StaffPointe, LLC - near Nashville , TN -
New York Pulmonologist/CC
StaffPointe, LLC - east, NY -
Wisconsin Physical Therapist
StaffPointe, LLC - Green Bay , WI
Events
- World Health Care Congress
April 14-16, 2009 — Washington, DC - World Healthcare Innovation & Technology Congress WHIT v.4.0
Dec 8-10 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
Boston Scientific, Medtronic slammed with renewed $600M award
September 17, 2008 — 2:30pm ET | By Anne Zieger
Eight years ago, Johnson & Johnson division Cordis Corp. was awarded almost $600 million in damages in a cardiac-stent infringement case against Boston Scientific Corp. and Medtronic. The cases involved the patent on Cordis's original Palmaz balloon expandable stent. However, the damages were set aside in 2000 and against in 2005 after successful appeals to jury verdicts in the cases. Now, a judge in Delaware has reinstated the awards, putting Boston Scientific on the hook for $324 million plus interest and Medtronic for $271 million plus interest.
To learn more about the case:
- read this Modern Healthcare article (reg. req.)
- read this Johnson & Johnson press release
Be the first to comment
Related Stories
- U.S. Senator questions partnership between cardiologists, medical devicemaker-backed group
- Drug companies plan to disclose grant funding
- Cardiologists stand by stents
- Defibrillator market faces problems
- Cambridge Heart Test wins Medicare approval
- Law could hurt device makers
- Guidant Merger Signifies Technological Shift
- Guidant competition leads to talk of St. Jude takeover
- Medtronic enters drug-eluting stent market
- Senators want info on who paid doctors
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





